GLP-1s include blockbuster diabetes medicines such as Ozempic and its weight-loss spinoff, Wegovy
[published correction appears in PLoS One
Lean Mass Vulnerability and Anabolic Suppression GLP-1RA therapy is frequently associated with reductions in lean body mass in clinical studies [40], although preclinical experiments have reported improvements in muscle function and mass under certain conditions [41,42,43]
Importantly, Pepto-Bismol should not be used in children under 16 years (due to risk of Reye's syndrome, particularly during viral illnesses), during pregnancy or breastfeeding, or by people with aspirin allergies
In-depth understanding of these mechanisms holds immense potential for advancing our comprehension of immunology and revolutionizing cancer therapeutic interventions
Right now, bold claims are being made about their efficacy, and the drugs, which are alarmingly easy to procure, are being self-administered long before research has had the opportunity to catch up